Y-mAbs Therapeutics (NASDAQ:YMAB) PT Lowered to $25.00

Y-mAbs Therapeutics (NASDAQ:YMAB) had its price objective cut by analysts at BMO Capital Markets from $26.00 to $25.00 in a report released on Tuesday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. BMO Capital Markets’ price objective points to a potential upside of 108.86% from the stock’s current price.

Other research analysts have also recently issued research reports about the company. HC Wainwright increased their price objective on Y-mAbs Therapeutics from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Monday, May 13th. Wedbush reissued an “outperform” rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday. Finally, Truist Financial started coverage on Y-mAbs Therapeutics in a research note on Friday, June 28th. They issued a “buy” rating and a $21.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $19.29.

Y-mAbs Therapeutics Stock Performance

Shares of NASDAQ YMAB opened at $11.97 on Tuesday. The business’s 50 day moving average price is $11.84 and its 200-day moving average price is $13.71. Y-mAbs Therapeutics has a fifty-two week low of $4.69 and a fifty-two week high of $20.90. The company has a market cap of $525.28 million, a price-to-earnings ratio of -24.43 and a beta of 0.66.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.08). Y-mAbs Therapeutics had a negative return on equity of 21.40% and a negative net margin of 25.64%. The business had revenue of $22.80 million during the quarter, compared to analysts’ expectations of $23.09 million. During the same quarter in the previous year, the company posted ($0.14) earnings per share. Sell-side analysts predict that Y-mAbs Therapeutics will post -0.52 earnings per share for the current year.

Insider Transactions at Y-mAbs Therapeutics

In other news, insider Thomas Gad sold 35,000 shares of the firm’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $12.03, for a total value of $421,050.00. Following the completion of the sale, the insider now owns 197,681 shares of the company’s stock, valued at approximately $2,378,102.43. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Thomas Gad sold 35,000 shares of the firm’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $12.03, for a total value of $421,050.00. Following the completion of the transaction, the insider now owns 197,681 shares in the company, valued at approximately $2,378,102.43. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Bo Kruse sold 31,371 shares of the firm’s stock in a transaction on Friday, May 31st. The stock was sold at an average price of $12.07, for a total value of $378,647.97. Following the completion of the transaction, the chief financial officer now owns 210,877 shares of the company’s stock, valued at approximately $2,545,285.39. The disclosure for this sale can be found here. Insiders sold 99,444 shares of company stock valued at $1,203,925 in the last quarter. 21.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Y-mAbs Therapeutics

A number of institutional investors have recently modified their holdings of YMAB. Tower Research Capital LLC TRC raised its stake in shares of Y-mAbs Therapeutics by 345.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,686 shares of the company’s stock valued at $46,000 after buying an additional 5,185 shares during the last quarter. Ameritas Investment Partners Inc. raised its stake in shares of Y-mAbs Therapeutics by 39.9% during the 1st quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock valued at $60,000 after buying an additional 1,056 shares during the last quarter. Bailard Inc. purchased a new position in shares of Y-mAbs Therapeutics during the 4th quarter valued at about $115,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Y-mAbs Therapeutics by 66.1% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 8,390 shares of the company’s stock valued at $136,000 after buying an additional 3,340 shares during the last quarter. Finally, SG Americas Securities LLC raised its stake in shares of Y-mAbs Therapeutics by 17.5% during the 4th quarter. SG Americas Securities LLC now owns 21,559 shares of the company’s stock valued at $147,000 after buying an additional 3,210 shares during the last quarter. Hedge funds and other institutional investors own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.